NO20055182L - Kombinasjon av makrolid T-celleimmunmodulator og et kalsiferol for behandling av hudsykdommer eller inflammatorisk tarmsykdom - Google Patents

Kombinasjon av makrolid T-celleimmunmodulator og et kalsiferol for behandling av hudsykdommer eller inflammatorisk tarmsykdom

Info

Publication number
NO20055182L
NO20055182L NO20055182A NO20055182A NO20055182L NO 20055182 L NO20055182 L NO 20055182L NO 20055182 A NO20055182 A NO 20055182A NO 20055182 A NO20055182 A NO 20055182A NO 20055182 L NO20055182 L NO 20055182L
Authority
NO
Norway
Prior art keywords
calciferol
macrolide
treatment
inflammatory bowel
bowel disease
Prior art date
Application number
NO20055182A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055182D0 (no
Inventor
Maximillan Grassberger
Stefan Hirsch
Josef Gottried Meingassner
Nabila Sekkat
Carle Paul
Karl Friedrich Mayer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20055182D0 publication Critical patent/NO20055182D0/no
Publication of NO20055182L publication Critical patent/NO20055182L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20055182A 2003-04-04 2005-11-03 Kombinasjon av makrolid T-celleimmunmodulator og et kalsiferol for behandling av hudsykdommer eller inflammatorisk tarmsykdom NO20055182L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307865.6A GB0307865D0 (en) 2003-04-04 2003-04-04 Pharmaceutical composition
PCT/EP2004/003512 WO2004087170A1 (en) 2003-04-04 2004-04-02 Combination of a macrolide t-cell immunomodulator and a calciferol for the treatment of skin diseases or of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
NO20055182D0 NO20055182D0 (no) 2005-11-03
NO20055182L true NO20055182L (no) 2006-01-03

Family

ID=9956228

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055182A NO20055182L (no) 2003-04-04 2005-11-03 Kombinasjon av makrolid T-celleimmunmodulator og et kalsiferol for behandling av hudsykdommer eller inflammatorisk tarmsykdom

Country Status (13)

Country Link
US (1) US20060106003A1 (pt)
EP (1) EP1613330A1 (pt)
JP (1) JP2006522058A (pt)
CN (1) CN1761470A (pt)
AU (1) AU2004226820B2 (pt)
BR (1) BRPI0409148A (pt)
CA (1) CA2519096A1 (pt)
GB (1) GB0307865D0 (pt)
IS (1) IS8092A (pt)
MX (1) MXPA05010702A (pt)
NO (1) NO20055182L (pt)
RS (1) RS20050668A (pt)
WO (1) WO2004087170A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022087526A1 (en) * 2020-10-23 2022-04-28 Massachusetts Institute Of Technology Methods and compositions for differentiating stem cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352671A (en) * 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
GB9004544D0 (en) * 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
JP3506474B2 (ja) * 1994-01-07 2004-03-15 帝人株式会社 安定性の向上した乾癬治療剤
JP3839502B2 (ja) * 1994-03-03 2006-11-01 帝人株式会社 湿疹・皮膚炎群治療剤
CA2270373A1 (en) * 1996-10-31 1998-05-07 American Home Products Corporation Synergistic composition comprising rapamycin and calcitriol
DE19744127B4 (de) * 1997-10-01 2006-10-05 Schering Ag Neue Vitamin D-Derivate mit Cyclopropylringen in den Seitenketten, Verfahren und Zwischenprodukte zu ihrer Herstellung sowie ihre Verwendung zur Herstellung von Arzneimitteln
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6358939B1 (en) * 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
CA2436195A1 (en) * 2001-02-09 2002-08-22 Kosan Biosciences, Inc. Laulimalide derivatives
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
EP1392323B1 (en) * 2001-05-22 2008-10-08 Bioxell S.p.a. Use of a vitamin d3 analogue for the treatment of autoimmune diabetes
US7887842B2 (en) * 2003-02-07 2011-02-15 Teikoku Pharma Usa, Inc. Methods of administering a dermatological agent to a subject

Also Published As

Publication number Publication date
EP1613330A1 (en) 2006-01-11
RS20050668A (sr) 2007-11-15
JP2006522058A (ja) 2006-09-28
GB0307865D0 (en) 2003-05-14
CN1761470A (zh) 2006-04-19
IS8092A (is) 2005-10-27
WO2004087170A1 (en) 2004-10-14
MXPA05010702A (es) 2005-12-12
BRPI0409148A (pt) 2006-05-09
AU2004226820B2 (en) 2008-02-21
CA2519096A1 (en) 2004-10-14
NO20055182D0 (no) 2005-11-03
AU2004226820A1 (en) 2004-10-14
WO2004087170B1 (en) 2004-11-25
US20060106003A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20070330L (no) Retinalderivater og fremgangsmater for anvendelse derav til behandling av synsforstyrrelser
ATE468027T1 (de) Oligosaccharidmischung
NO20081041L (no) PPar aktive forbindelser
MY147247A (en) Organic compounds and their uses
NO20076072L (no) Tigecyklin og metoder for fremstilling av 9-nitrominocyklin
NO20075997L (no) Methoder til furifysering av tigecyklin
NO20045301L (no) Substituert 1,3-diphenylprop-2-en-1-one derivat, fremstilling og anvendelse derav.
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20075068L (no) Lipocalinprotein
WO2006088923A3 (en) A food containing a probiotic and an isolated beta-glucan and methods of use thereof
TW200716646A (en) (S)-N-methylnaltrexone
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
NO20060871L (no) Azepinderivater som farmasoytiske midler
NO20075998L (no) Tigecyklin og metoder til fremstilling av 9-aminominocyklin
NO20081479L (no) 7-(2-Amino-1-hydroksyetyl)-4-hydroksybenzotiazol-2(3H)-ondenvater som beta2-adrenoceptoragonister
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
WO2005027977A3 (en) Diclofenac compositions for the treatment of skin disorders
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application